Mark Pascuzzi
Obstetrics & Gynecology · Winchester, KYNPI 1033164207
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $418 and has fallen 58.5% since, to $174 in 2025.
Across 77 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$341
- Astellas Pharma US Inc$147
- Hologic Sales And Service, LLC$132
- Bayer$116
- Gynesonics, Inc.$80
- Axsome Therapeutics, Inc.$70
- plus $542 from 19 others
What the payments were for
- Food & beverage$1,39097%
- Education$383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $341 |
| Astellas Pharma US Inc | 8 | $147 |
| Hologic Sales And Service, LLC | 5 | $132 |
| Bayer | 7 | $116 |
| Gynesonics, Inc. | 2 | $80 |
| Axsome Therapeutics, Inc. | 3 | $70 |
| Sage Therapeutics, LLC | 4 | $64 |
| Pfizer | 3 | $58 |
| Myovant Sciences Inc. | 3 | $54 |
| Lupin Inc. | 3 | $52 |
| AMAG Pharmaceuticals, Inc. | 3 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Therapeuticsmd, Inc. | 2 | $33 |
| Duchesnay USA Incorporated | 2 | $31 |
| BD | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Mayne Pharma Commercial LLC | 2 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Agile Therapeutics, Inc. | 1 | $17 |
| Evofem Biosciences, Inc. | 1 | $15 |
| Davol Inc. | 1 | $15 |
| Millicent US Inc | 1 | $14 |
| Minerva Surgical, Inc | 1 | $13 |
| Merck | 1 | $11 |
| Mylan Pharmaceuticals Inc. | 1 | $11 |
How this compares
$1,428 in reported general payments places this provider in the 60th percentile of 474 obstetrics & gynecology providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 22 | $16,948 |
| Ibandronate Sodium | 14 | $255 |
| Clobetasol Propionate | 13 | $242 |
| Nystatin | 11 | $229 |
| Fluconazole | 47 | $120 |
| Metronidazole | 11 | $70 |
| Alendronate Sodium | 13 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $147 | $16,94822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 474 obstetrics & gynecology providers in Kentucky.
Other obstetrics & gynecology in Winchester
- Ramon ThomasWinchester$14K
- Leigh DoaneWinchester$12K
- Nathan SticeBowling Green$199K
- John BrunerSomerset$82K
- Resad PasicLouisville$39K
- Wendy JacksonLexington$37K
- Bradley YoukilisLouisville$29K
- Travis GilbertCorbin$28K
- James GuilerLexington$25K
- Gigi GirardLouisville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.